literature

SARS_CoV_2 mutation literature information.

Tracking SARS-CoV-2 Spike Protein Mutations in the United States (2020/01 - 2021/03) Using a Statistical Learning Strategy.

PMID: 34159336 2021 bioRxiv

Result: The S13I and W152C mutations, which are situated in the N-terminal domain (NTD) of the Spike protein, have been implicated in escape from NTD-targeting monoclonal antibodies.

Result: The VRV-haplotype S13I-W152C-L452R (ICR-3) appeared in Fall 2020 and is rapidly becoming dominant in states on the West Coast, as well as appearing in selected Southwestern and Southeastern states.

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity.

PMID: 34171266 2021 Cell host & microbe

Method: Plasmids expressing the SARS-CoV-2 S protein mutants (pC-S-L452R, pC-SARS2-S-Y453F, pC-SARS2-S-N501Y, pC-SARS2-S-B.1.429 [S13I/W152C/L452R/D614G] and pC-SARS2-S-B.1.1.298 [HV69-70del/Y453F/D614G]) were generated by site-directed mutagenesis PCR using pC-SARS2-S (kindly provided by Kenzo Tokunaga) as the template and the following primers: S forward,

Table: S13I

Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?

PMID: 34206453 2021 Viruses

Introduction: This variant (Epsilon) comprises two separate lineages B.1.427 and B.1.429, the first carrying two spike mutations (L452R, D614G) and the second carrying four (S13I, W152C, L452R, D614G).

Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants.

PMID: 34207378 2021 Viruses

Introduction: It derives from the B line (B.1.429 and B.1.427) and carries three mutations on the Spike: S13I, W152C, and, most notably, L452R, located in the RBD and potentially involved in mAbs neutralization escape (Table 1).

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.

PMID: 34210893 2021 Science (New York, N.Y.)

Abstract: A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), which was originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD).

Abstract: The S13I and W152C mutations resulted in total loss of neutralization for 10 of 10 NTD-specific mAbs because the NTD antigenic supersite was remodeled by a shift of the signal peptide cleavage site and the formation of a new disulfide bond, as revealed by mass spectrometry and structural studies.

Temporal landscape of mutational frequencies in SARS-CoV-2 genomes of Bangladesh: possible implications from the ongoing outbreak in Bangladesh.

PMID: 34251592 2021 Virus genes

Result: In our analysis, more than 20 nonsynonymous mutation sites were identified in the S protein, in which 13 (S13I, Q14H, P26L, H49Y, G75V, T75I, S95F, T95I, V127F, D138H, N211Y, Y248H, and S255F) were observed in the N-terminal domain (NTD).

Emerging mutation in SARS-CoV-2 spike: Widening distribution over time in different geographic areas.

PMID: 34271250 2021 Biomedical journal

Result: In addition, there were mutation types that have more than one case such as in Asia, the mutations A829T (n = 3), P25L (n = 2), V367F (n = 2), R682Q (n = 2), S13I (n = 2), and T22I (n = 2) while the other types have just one case.

Table: S13I

Discussion: Apart from D614G, we also identified other mutations in the S1 subunit namely L5F and S13I which are in the signal peptide (SP) domain.

Mutational analysis in international isolates and drug repurposing against SARS-CoV-2 spike protein: molecular docking and simulation approach.

PMID: 34307771 2021 Virusdisease

Table: S13I

Browser Board

Co-occurred Entities

Filtrator